CA2563401A1 - Derives d'imidazole servant d'inhibiteurs de tafia - Google Patents

Derives d'imidazole servant d'inhibiteurs de tafia Download PDF

Info

Publication number: CA2563401A1
Authority: CA; Canada
Prior art keywords: alkyl; twice; unsubstituted; substituted independently; another once
Prior art date: 2004-04-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA002563401A

Other languages

English (en)

Other versions

CA2563401C (fr

Inventor

Christopher Kallus

Holger Heitsch

Andreas Lindenschmidt

Sven Grueneberg

Hauke Szillat

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Aventis Deutschland GmbH

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-22

Filing date

2005-04-07

Publication date

2005-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2563401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-04-07 Application filed by Individual filed Critical Individual

2005-11-10 Publication of CA2563401A1 publication Critical patent/CA2563401A1/fr

2012-08-07 Application granted granted Critical

2012-08-07 Publication of CA2563401C publication Critical patent/CA2563401C/fr

2025-04-07 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CA2563401A 2004-04-22 2005-04-07 Derives d'imidazole servant d'inhibiteurs de tafia Expired - Fee Related CA2563401C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE102004020186.2		2004-04-22
DE102004020186A DE102004020186A1 (de)	2004-04-22	2004-04-22	Heterocyclylessigsäuren als Inhibitoren von TAFla
PCT/EP2005/003630 WO2005105781A1 (fr)	2004-04-22	2005-04-07	Derives d'imidazole servant d'inhibiteurs de tafia

Publications (2)

Publication Number	Publication Date
CA2563401A1 true CA2563401A1 (fr)	2005-11-10
CA2563401C CA2563401C (fr)	2012-08-07

Family

ID=34964308

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2563401A Expired - Fee Related CA2563401C (fr)	2004-04-22	2005-04-07	Derives d'imidazole servant d'inhibiteurs de tafia

Country Status (34)

Country	Link
EP (2)	EP1740569B1 (fr)
JP (1)	JP4939401B2 (fr)
KR (1)	KR101162047B1 (fr)
CN (1)	CN100572376C (fr)
AR (1)	AR053302A1 (fr)
AT (2)	ATE386737T1 (fr)
AU (1)	AU2005238144B2 (fr)
BR (1)	BRPI0510159A (fr)
CA (1)	CA2563401C (fr)
CR (1)	CR8650A (fr)
CY (1)	CY1108087T1 (fr)
DE (2)	DE102004020186A1 (fr)
DK (1)	DK1740569T3 (fr)
EC (1)	ECSP066941A (fr)
ES (1)	ES2299026T3 (fr)
HR (1)	HRP20080099T3 (fr)
IL (1)	IL178672A (fr)
MA (1)	MA28543B1 (fr)
MY (1)	MY140903A (fr)
NI (1)	NI200600217A (fr)
NO (1)	NO20065320L (fr)
NZ (1)	NZ550757A (fr)
PE (1)	PE20060172A1 (fr)
PL (1)	PL1740569T3 (fr)
PT (1)	PT1740569E (fr)
RS (1)	RS50553B (fr)
RU (1)	RU2375356C2 (fr)
SI (1)	SI1740569T1 (fr)
TN (1)	TNSN06341A1 (fr)
TW (1)	TWI359016B (fr)
UA (1)	UA87306C2 (fr)
UY (1)	UY28868A1 (fr)
WO (1)	WO2005105781A1 (fr)
ZA (1)	ZA200607668B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010130718A1 (fr) *	2009-05-15	2010-11-18	Sanofi-Aventis	Procédé de préparation d'un composé utile comme inhibiteur de tafia
US9340531B2 (en)	2010-03-18	2016-05-17	Daiichi Sankyo Company, Limited	Cycloalkyl-substituted imidazole derivative
US9662310B2 (en)	2010-03-18	2017-05-30	Daiichi Sankyo Company, Limited	Cyclopropanecarboxylic acid derivative

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20150514T1 (hr) *	2006-12-06	2015-09-11	Sanofi	DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008100459A1 (fr) *	2007-02-13	2008-08-21	Schering Corporation	Dérivés et analogues de chromane en tant qu'agonistes fonctionnellement sélectifs des récepteurs adrénergiques alpha2c
AU2008279447A1 (en)	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2262783A2 (fr) *	2008-02-21	2010-12-22	Sanofi-Aventis	Sondes d'imagerie à liaison covalente
CN102056922B (zh)	2008-06-06	2013-11-20	赛诺菲-安万特	作为tafia抑制剂的大环脲和磺酰胺衍生物
JPWO2010050525A1 (ja)	2008-10-29	2012-03-29	大正製薬株式会社	ＴＡＦＩａ阻害活性を有する化合物
FR2947266B1 (fr) *	2009-06-26	2011-06-17	Servier Lab	Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011041154A1 (fr)	2009-10-01	2011-04-07	Metabolex, Inc.	Sels de la tétrazol-1-yl-phénoxyméthyl-thiazol-2-yl-pipéridinyl-pyrimidine substituée
EP2638016B1 (fr)	2010-11-11	2014-10-01	Sanofi	Procédé de préparation de dérivés de l'acide 3-(6-amino-pyridin-3yl)-2-acrylique
US9145385B2 (en)	2011-11-25	2015-09-29	Sanofi	Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
US9102657B2 (en) *	2011-11-25	2015-08-11	Sanofi	Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
WO2013076177A1 (fr)	2011-11-25	2013-05-30	Sanofi	Sel d'éthylester d'acide (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1-h-imidazol-4-yl)- propionique
EP2805705B1 (fr)	2013-05-23	2016-11-09	IP Gesellschaft für Management mbH	Emballage comprenant des unités d'administration des sels de sodium de l'acide (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionique
BR112015029667A2 (pt)	2013-06-10	2017-07-25	Sanofi Sa	derivados de ureia macrocíclica como inibidores de tafia, sua preparação e seus usos como produtos farmacêuticos
US20190117624A1 (en)	2016-03-29	2019-04-25	Daiichi Sankyo Company, Limited	Therapeutic agent for inflammatory bowel diseases
CA3032432A1 (fr)	2016-08-03	2018-02-08	Charles A. Mcwherter	Composes d'aryle d'oxymethylene pour le traitement de maladies gastro-intestinales inflammatoires ou de troubles gastro-intestinaux

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2292262T3 (es) *	1998-12-24	2008-03-01	Astellas Pharma Inc.	Compuestos de imidazol y su uso medicinal.
WO2003013526A1 (fr) *	2001-08-08	2003-02-20	Merck & Co. Inc.	Composes anticoagulants
MXPA04005940A (es)	2002-01-22	2004-09-13	Pfizer	Acidos 3-(imidazolil)-2-aminopropanoicos.

2004
- 2004-04-22 DE DE102004020186A patent/DE102004020186A1/de not_active Withdrawn
2005
- 2005-04-06 PE PE2005000382A patent/PE20060172A1/es not_active Application Discontinuation
- 2005-04-07 RU RU2006141246/04A patent/RU2375356C2/ru not_active IP Right Cessation
- 2005-04-07 CN CNB2005800115593A patent/CN100572376C/zh not_active Expired - Fee Related
- 2005-04-07 SI SI200530185T patent/SI1740569T1/sl unknown
- 2005-04-07 JP JP2007508756A patent/JP4939401B2/ja not_active Expired - Fee Related
- 2005-04-07 AT AT05731221T patent/ATE386737T1/de active
- 2005-04-07 DE DE502005002927T patent/DE502005002927D1/de not_active Expired - Lifetime
- 2005-04-07 HR HR20080099T patent/HRP20080099T3/xx unknown
- 2005-04-07 PL PL05731221T patent/PL1740569T3/pl unknown
- 2005-04-07 AU AU2005238144A patent/AU2005238144B2/en not_active Ceased
- 2005-04-07 AT AT07017340T patent/ATE523505T1/de active
- 2005-04-07 PT PT05731221T patent/PT1740569E/pt unknown
- 2005-04-07 ES ES05731221T patent/ES2299026T3/es not_active Expired - Lifetime
- 2005-04-07 WO PCT/EP2005/003630 patent/WO2005105781A1/fr not_active Ceased
- 2005-04-07 KR KR1020067021881A patent/KR101162047B1/ko not_active Expired - Fee Related
- 2005-04-07 BR BRPI0510159-0A patent/BRPI0510159A/pt not_active Application Discontinuation
- 2005-04-07 EP EP05731221A patent/EP1740569B1/fr not_active Expired - Lifetime
- 2005-04-07 RS RSP-2008/0107A patent/RS50553B/sr unknown
- 2005-04-07 DK DK05731221T patent/DK1740569T3/da active
- 2005-04-07 EP EP07017340A patent/EP1864979B1/fr not_active Expired - Lifetime
- 2005-04-07 NZ NZ550757A patent/NZ550757A/en not_active IP Right Cessation
- 2005-04-07 CA CA2563401A patent/CA2563401C/fr not_active Expired - Fee Related
- 2005-04-20 TW TW094112493A patent/TWI359016B/zh not_active IP Right Cessation
- 2005-04-20 MY MYPI20051748A patent/MY140903A/en unknown
- 2005-04-20 AR ARP050101556A patent/AR053302A1/es not_active Application Discontinuation
- 2005-04-22 UY UY28868A patent/UY28868A1/es unknown
- 2005-07-04 UA UAA200612254A patent/UA87306C2/ru unknown
2006
- 2006-09-13 ZA ZA200607668A patent/ZA200607668B/en unknown
- 2006-09-20 NI NI200600217A patent/NI200600217A/es unknown
- 2006-09-22 CR CR8650A patent/CR8650A/es unknown
- 2006-10-17 IL IL178672A patent/IL178672A/en not_active IP Right Cessation
- 2006-10-19 MA MA29399A patent/MA28543B1/fr unknown
- 2006-10-20 EC EC2006006941A patent/ECSP066941A/es unknown
- 2006-10-20 TN TNP2006000341A patent/TNSN06341A1/en unknown
- 2006-11-20 NO NO20065320A patent/NO20065320L/no not_active Application Discontinuation
2008
- 2008-05-12 CY CY20081100491T patent/CY1108087T1/el unknown

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010130718A1 (fr) *	2009-05-15	2010-11-18	Sanofi-Aventis	Procédé de préparation d'un composé utile comme inhibiteur de tafia
US8865906B2 (en)	2009-05-15	2014-10-21	Sanofi	Process for the preparation of a compound useful as an inhibitor of TAFIa
AU2010247431B2 (en) *	2009-05-15	2015-02-19	Sanofi	Process for the preparation of a compound useful as an inhibitor of TAFIa
US9340531B2 (en)	2010-03-18	2016-05-17	Daiichi Sankyo Company, Limited	Cycloalkyl-substituted imidazole derivative
US9662310B2 (en)	2010-03-18	2017-05-30	Daiichi Sankyo Company, Limited	Cyclopropanecarboxylic acid derivative

Also Published As

Publication number	Publication date
MY140903A (en)	2010-01-29
IL178672A (en)	2011-08-31
KR101162047B1 (ko)	2012-07-04
CN1950357A (zh)	2007-04-18
UY28868A1 (es)	2005-11-30
RU2375356C2 (ru)	2009-12-10
NO20065320L (no)	2007-01-12
TW200602325A (en)	2006-01-16
EP1864979A1 (fr)	2007-12-12
KR20070007346A (ko)	2007-01-15
EP1740569B1 (fr)	2008-02-20
ES2299026T3 (es)	2008-05-16
SI1740569T1 (sl)	2008-06-30
JP2007533672A (ja)	2007-11-22
NI200600217A (es)	2008-06-17
RS50553B (sr)	2010-05-07
WO2005105781A1 (fr)	2005-11-10
BRPI0510159A (pt)	2007-10-02
EP1864979B1 (fr)	2011-09-07
AR053302A1 (es)	2007-05-02
EP1740569A1 (fr)	2007-01-10
TNSN06341A1 (en)	2008-02-22
NZ550757A (en)	2010-06-25
DK1740569T3 (da)	2008-06-02
TWI359016B (en)	2012-03-01
PL1740569T3 (pl)	2008-07-31
CN100572376C (zh)	2009-12-23
DE502005002927D1 (de)	2008-04-03
ATE386737T1 (de)	2008-03-15
MA28543B1 (fr)	2007-04-03
DE102004020186A1 (de)	2005-11-17
CR8650A (es)	2007-12-04
HK1101823A1 (zh)	2007-10-26
ATE523505T1 (de)	2011-09-15
AU2005238144B2 (en)	2010-08-26
IL178672A0 (en)	2007-02-11
ZA200607668B (en)	2008-03-26
ECSP066941A (es)	2006-12-20
JP4939401B2 (ja)	2012-05-23
PE20060172A1 (es)	2006-03-31
AU2005238144A1 (en)	2005-11-10
PT1740569E (pt)	2008-03-31
UA87306C2 (en)	2009-07-10
RU2006141246A (ru)	2008-06-10
CY1108087T1 (el)	2014-02-12
HRP20080099T3 (en)	2008-03-31
CA2563401C (fr)	2012-08-07

Publication	Publication Date	Title
CA2563401A1 (fr)	2005-11-10	Derives d'imidazole servant d'inhibiteurs de tafia
US6403595B1 (en)	2002-06-11	Sulfonamide derivatives, processes for producing the same and utilization thereof
US6562978B1 (en)	2003-05-13	Cyclic amine compounds as CCR5 antagonists
CN101001851B (zh)	2011-04-20	具有作为组蛋白脱乙酰酶(hdac)抑制剂的活性的羟基酰胺化合物
CN100352807C (zh)	2007-12-05	被取代的哌啶化合物
ZA200407665B (en)	2005-08-29	New compounds.
HUP0402567A2 (hu)	2005-03-29	Piperidinszármazékok és alkalmazásuk kemokin receptor (különösen CCR5) aktivitás modulátoraiként
WO1999064392A1 (fr)	1999-12-16	Derive de benzamidine
US8710232B2 (en)	2014-04-29	Imidazole derivatives used as TAFIa inhibitors
HRP20150514T1 (hr)	2015-09-11	DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
EP1188755B1 (fr)	2006-05-03	Derives d'acylhydrazines, procede pour leur preparation et utilisation
CA2655633A1 (fr)	2008-01-10	Nouveaux analogues de pyridine
AU2002211280A1 (en)	2002-04-08	Piperazin-2-one amides as inhibitors of factor Xa
JPH11236372A (ja)	1999-08-31	スルホンアミド誘導体、その製造方法及び剤
JP2000204081A (ja)	2000-07-25	スルホンアミド誘導体、その製造法及び用途
MXPA06011067A (en)	2007-04-20	Imidazole derivatives used as tafia inhibitors
HK1101823B (en)	2010-09-10	Imidazole derivatives used as tafia inhibitors
JPWO2000078747A1 (ja)	2003-01-14	アシルヒドラジン誘導体、その製造法及び用途
JPWO1999064392A1 (ja)	2002-11-19	ベンズアミジン誘導体
JPWO1999040075A1 (ja)	2002-10-02	スルホンアミド誘導体、その製造法及び用途
JP2001278882A (ja)	2001-10-10	アシルヒドラジン誘導体、その製造法及び用途

Legal Events

Date	Code	Title	Description
2010-03-09	EEER	Examination request
2019-05-20	MKLA	Lapsed	Effective date: 20190408